- Home
- DMAC vs AMCX Comparison
DMAC vs AMCX Comparison
Compare DMAC & AMCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- AMCX
- Stock Information
- Founded
- DMAC 2000
- AMCX 1980
- Country
- DMAC United States
- AMCX United States
- Employees
- DMAC N/A
- AMCX 1800
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- AMCX Cable & Other Pay Television Services
- Sector
- DMAC Health Care
- AMCX Telecommunications
- Exchange
- DMAC Nasdaq
- AMCX Nasdaq
- Market Cap
- DMAC 321.5M
- AMCX 339.5M
- IPO Year
- DMAC N/A
- AMCX 2011
- Fundamental
- Price
- DMAC $5.95
- AMCX $7.77
- Analyst Decision
- DMAC Strong Buy
- AMCX Sell
- Analyst Count
- DMAC 4
- AMCX 4
- Target Price
- DMAC $15.50
- AMCX $6.38
- AVG Volume (30 Days)
- DMAC 315.3K
- AMCX 381.5K
- Earning Date
- DMAC 11-12-2025
- AMCX 11-07-2025
- Dividend Yield
- DMAC N/A
- AMCX N/A
- EPS Growth
- DMAC N/A
- AMCX N/A
- EPS
- DMAC N/A
- AMCX N/A
- Revenue
- DMAC N/A
- AMCX $2,316,303,000.00
- Revenue This Year
- DMAC N/A
- AMCX N/A
- Revenue Next Year
- DMAC N/A
- AMCX N/A
- P/E Ratio
- DMAC N/A
- AMCX N/A
- Revenue Growth
- DMAC N/A
- AMCX N/A
- 52 Week Low
- DMAC $3.19
- AMCX $5.41
- 52 Week High
- DMAC $7.49
- AMCX $10.60
- Technical
- Relative Strength Index (RSI)
- DMAC 42.03
- AMCX 52.46
- Support Level
- DMAC $5.26
- AMCX $6.98
- Resistance Level
- DMAC $6.47
- AMCX $8.40
- Average True Range (ATR)
- DMAC 0.41
- AMCX 0.34
- MACD
- DMAC -0.10
- AMCX 0.06
- Stochastic Oscillator
- DMAC 36.50
- AMCX 54.22
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About AMCX AMC Networks Inc.
AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached 60 million pay-TV households in the US at the end of 2024. The firm also had nearly 12.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.